|
81 |
Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date
Enthalten in BioDrugs Bd. 34, 8.1.2020, Nr. 2, date:4.2020: 111-119
|
|
|
|
82 |
Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment
Enthalten in Current treatment options in oncology Bd. 23, 19.2.2022, Nr. 2, date:2.2022: 155-170
|
|
|
|
83 |
Bispecific antibodies in clinical practice: Understanding recent advances and current place in cancer treatment landscape
Enthalten in Clinical and experimental medicine Bd. 25, 28.11.2024, Nr. 1, date:12.2025: 1-5
|
|
|
|
84 |
Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?
Enthalten in Current oncology reports Bd. 21, 4.2.2019, Nr. 2, date:2.2019: 1-6
|
|
|
|
85 |
Bispecific antibodies in the treatment of multiple myeloma
Enthalten in Blood cancer journal Bd. 14, 12.9.2024, Nr. 1, date:12.2024: 1-17
|
|
|
|
86 |
Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells
Enthalten in Nature immunology Bd. 25, 26.1.2024, Nr. 3, date:3.2024: 462-470
|
|
|
|
87 |
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
Enthalten in Blood cancer journal Bd. 14, 5.12.2024, Nr. 1, date:12.2024: 1-8
|
|
|
|
88 |
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
Enthalten in Journal of hematology & oncology Bd. 16, 3.8.2023, Nr. 1, date:12.2023: 1-4
|
|
|
|
89 |
Bispecific Antibodies: Formats and Areas of Application
Enthalten in Molecular biology Bd. 52, 14.6.2018, Nr. 3, date:5.2018: 323-334
|
|
|
|
90 |
Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast
Enthalten in Advances in therapy Bd. 40, 16.6.2023, Nr. 8, date:8.2023: 3291-3303
|
|
Administration
